Mutlu Murat, Altundoğan Serpil, Kocamaz Ömer Faruk
Faculty of Dentistry, Department of Oral and Maxillofacial Surgery, Ankara University, Ankara, Türkiye.
BMC Oral Health. 2025 Jul 2;25(1):985. doi: 10.1186/s12903-025-06490-5.
MRONJ (Medication-Related Osteonecrosis of the Jaw) refers to a condition characterized by osteonecrosis of the jawbone associated with the use of certain medications. One of the most common causes of MRONJ is bisphosphonates, which are frequently used today to treat osteoporosis, metabolic bone diseases, and the skeletal effects of malignancies.
The aim of this study is to assess the awareness and approaches of medical doctors who prescribe bisphosphonate group drugs regarding MRONJ.
A total of 125 physicians specializing in the departments of oncology, orthopedics and traumatology, physical medicine and rehabilitation, and obstetrics and gynecology participated in our study. The participants completed questionnaire forms consisting of 15 questions related to MRONJ, and the results were analyzed.
The specialists who participated in the study were found to prescribe zoledronate and alendronate more frequently than other antiresorptive medications. Over the past year, when examining the frequency of encountering patients with MRONJ, 56% of physicians had not encountered any cases, while 44% had encountered between one and four cases. The group that most frequently requested consultations from physicians regarding bisphosphonates was identified as dentists, with a rate of 50.4%, followed by oral and maxillofacial surgeons at 36.8%. The specialists who participated in the study reported that when they encounter patients with osteonecrosis, 39.2% most frequently referred them to oral and maxillofacial surgery.
To enhance awareness of MRONJ, a multidisciplinary approach should be adopted between medical and dental disciplines, and a well-coordinated consultation system should be established. This will ensure that patients undergo dental examinations and complete necessary interventional dental procedures before commencing antiresorptive drug therapy. Furthermore, implementing educational strategies such as academic publications, training seminars, and symposia is of great importance to increase the level of awareness on this issue.
药物相关性颌骨坏死(MRONJ)是指与某些药物使用相关的颌骨骨坏死病症。MRONJ最常见的病因之一是双膦酸盐类药物,如今这类药物常用于治疗骨质疏松症、代谢性骨病以及恶性肿瘤的骨骼影响。
本研究旨在评估开具双膦酸盐类药物的医生对MRONJ的认知情况及处理方法。
共有125名分别来自肿瘤学、骨科与创伤学、物理医学与康复学以及妇产科的医生参与了我们的研究。参与者填写了由15个与MRONJ相关问题组成的问卷,并对结果进行了分析。
参与研究的专家中,唑来膦酸和阿仑膦酸的处方频率高于其他抗吸收药物。在过去一年中,在检查遇到MRONJ患者的频率时,56%的医生未遇到任何病例,而44%的医生遇到了1至4例病例。就双膦酸盐类药物最常向医生咨询的群体中牙科医生占比最高,为50.4%,其次是口腔颌面外科医生,占36.8%。参与研究的专家报告称,当遇到骨坏死患者时,39.2%的专家最常将他们转诊至口腔颌面外科。
为提高对MRONJ的认知,应在医学和牙科领域采取多学科方法,并建立协调良好的咨询系统。这将确保患者在开始抗吸收药物治疗前接受牙科检查并完成必要的介入性牙科程序。此外,实施学术出版物、培训研讨会和专题讨论会等教育策略对于提高对该问题的认知水平非常重要。